Abstract: The present disclosure provides an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a sulfur-containing compound having a specified structure.

Abstract: The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (?)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.

Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.

Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

Abstract: Provided is a sliding member, method for manufacturing sliding member, and compressor swash plate using sliding member in which adhesion between the substrate and the resin is enhanced, and which has the excellent durability whereby peeling of the resin film from the substrate does not occur due to prolonged sliding even under harsh load conditions. The sliding member provides a substrate irradiated laser light with energy intensity per unit area of 0.053 J/mm2 or more and configured an uneven part formed toward a vertical direction by the irradiated laser light and a melted and solidified portion on the uneven part and a resin film including solid lubricant and a binder resin on the substrate.

Abstract: Provided is a sliding member, method for manufacturing sliding member, and compressor swash plate using sliding member in which adhesion between the substrate and the resin is enhanced, and which has the excellent durability whereby peeling of the resin film from the substrate does not occur due to prolonged sliding even under harsh load conditions. The sliding member provides a substrate irradiated laser light with energy intensity per unit area of 0.053 J/mm2 or more and configured an uneven part formed toward a vertical direction by the irradiated laser light and a melted and solidified portion on the uneven part and a resin film including solid lubricant and a binder resin on the substrate.

Abstract: A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

Abstract: Provided is a method for disposal of radioactive waste which can reduce the radiation level until the waste can be reused as landfill or the like and which prevents the leakage of radiation nuclides in the ground. The method includes the following: a primary treatment step of turning the radioactive waste into a radioactive waste (primary treated waste) which has a radiation level equal to or less than a reference value via a radiation shielding agent composed of or predominantly composed of a Ca-based inorganic compound; and a secondary treatment step of heating to melt the primary treated waste and thereafter cooling the same to glass granules, and then sealing radioactive nuclides in the glass body.

Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).

Abstract: A method for treating a non-ocular inflammatory disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the following formula (1) or a salt thereof: R1 represents: R2 represents a lower alkyl group, a lower cycloalkyl group or an aralkyl group; R3 represents a lower alkyl group; R4, R5, R6 or R7 each represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a cyano group or a nitro group; m, n, p or q each represents 0, 1 or 2; in the case where m, n, p or q is 2, each of R4, R5, R6 or R7 is the same or different.

Abstract: A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

Abstract: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound.

Abstract: A method for preventing or treating a metabolic disorder, an inflammatory disease, an autoimmune disease, an allergic disease, a central nervous system disease, a cardiovascular disease, a homeostasis-related disease or glaucoma, involving administering a compound or a salt thereof, the compound having the following formula (1): wherein R1 represents alkyl, cycloalkyl, aryl, heterocyclic or aralkyl; R7 represents cycloalkyl, aryl or heterocyclic; W represents oxygen or NR8, Y represents alkylene, Z represents oxygen, sulfur, OCO or NR9; R2, R3, R4, R6, R8 and R9 represent hydrogen or alkyl.